Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy

J. D. Workum 1,2*, C. Kramers 2, E. Kolwijck 3,4, J. A. Schouten 1,4, S. N. de Wildt 1,2,5† and R. J. Bru¨ggemann 2,6†

1Department of Intensive Care, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; 2Department of Pharmacology and Toxicology, Radboud Institute Health Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; 3Department of Medical Microbiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; 4Radboud Center for Infectious Diseases, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; 5Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, Wytemaweg 80, 3015 CN, The Netherlands; 6Department of Pharmacy, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands

*Corresponding author. Present address: Radboud University Medical Center, Department of Intensive Care Medicine, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. E-mail: Jessica.Workum@radboudumc.nl

†Contributed equally to this work.

Received 20 June 2020; accepted 16 August 2020

Objectives: Piperacillin/tazobactam combined with vancomycin has been associated with a decline in renal function when compared with monotherapy. Teicoplanin is a glycopeptide similar to vancomycin. We investigated whether piperacillin/tazobactam combined with teicoplanin is associated with a decline in renal function as well.

Methods: We conducted a single-centre retrospective cohort study with data from our electronic health records from 9 August 2013 to 15 November 2019, including all adult patients that received either piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam + teicoplanin. The incidence of acute kidney injury (AKI) at 48–72 h served as the primary outcome, whereas change in serum creatinine served as a secondary outcome.

Results: Of the 4202 included patients, 3188 (75.9%) received piperacillin/tazobactam, 791 (18.8%) received teicoplanin and 223 (5.3%) received piperacillin/tazobactam + teicoplanin. The incidence of AKI at 48–72 h after commencement of antibiotic therapy was 5.4% for piperacillin/tazobactam, 3.4% for teicoplanin and 11.7% for piperacillin/tazobactam + teicoplanin (P < 0.001). However, mean serum creatinine at 48–72 h was slightly higher in the piperacillin/tazobactam + teicoplanin group therapy compared with baseline [+1.61% (95% CI –2.25 to 5.70)], indicating a slight decrease in renal function, and decreased for piperacillin/tazobactam [–1.98% (95% CI –2.73 to –1.22)] and teicoplanin [–8.01% (95% CI –9.54 to –6.45)]. After correcting for significant confounders in a multivariate linear regression analysis, these patterns remained.

Conclusions: Our study suggests that piperacillin/tazobactam + teicoplanin is associated with a higher prevalence of AKI compared with monotherapy. However, as the overall decline in renal function with piperacillin/tazobactam + teicoplanin is very small, its clinical relevance is likely limited. Therefore, piperacillin/tazobactam + teicoplanin can probably be safely combined.

Introduction

Healthcare-associated infections frequently require both Pseudomonas spp. and either MRSA, coagulase-negative Staphylococcus spp. or Enterococcus faecium coverage. Accordingly, a commonly used combination of antibiotics consists of piperacillin/tazobactam and vancomycin. The nephrotoxicity of vancomycin has been well recognized, occurring in up to 40% of patients depending on the dose.1,2 Though its mechanism is not completely understood, it is hypothesized that vancomycin causes oxidative effects on the proximal renal tubule, resulting in renal tubular ischaemia. Risk factors for developing vancomycin-related nephrotoxicity include dose, duration of therapy, severity of illness and chronic kidney disease.3 Teicoplanin is a glycopeptide with chemical and microbiological properties similar to vancomycin.4 Teicoplanin is shown to be equally effective in terms of treatment outcomes when compared with vancomycin, but with significantly less nephrotoxicity.5–7 A Cochrane systematic review concluded that teicoplanin reduced the risk of nephrotoxicity...
Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy

Methods

Study design and setting

We performed a single-centre retrospective cohort analysis using patient data collected from the electronic medical records at Radboud University Medical Center (Radboudumc), a tertiary hospital in the Netherlands. As this study consisted of retrospective anonymized data, the need for formal ethics approval was waived by the Radboudumc Research Ethics Board according to the Dutch Law of Human Research.

Patients

Patients were selected when hospitalized between 9 August 2013 and 15 November 2019. Patients were included if they were at least 18 years of age, received piperacillin/tazobactam, teicoplanin or both simultaneously (piperacillin/tazobactam + teicoplanin) at any time during admission. Patients were excluded if no serum creatinine level was available from 7 days prior to admission until commencement of antibiotic treatment or at 48–72 h after commencement, if they had an estimated glomerular filtration rate (eGFR) ≤ 30 mL/min before admission, if they were diagnosed with AKI at admission, or if they received renal replacement therapy before or during admission. Patients were also excluded if they received piperacillin/tazobactam and teicoplanin without overlap during admission. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, as an increase in serum creatinine by ≥ 26.5 μmol/L within 48 h or as an increase in serum creatinine level by ≥ 50% from baseline. We did not take urine output into account for the definition of AKI as these data were not available.

Statistical analyses

Patient characteristics were described with basic descriptive statistics. Continuous variables were compared with a one-way analysis of variance (ANOVA) and categorical variables were compared with a Pearson’s χ² test. To satisfy the assumption of underlying linearity, the log-transformed data were considered regarding serum creatinine. Data were analysed for the overall study population, and the ICU and non-ICU population separately. To gain insight into our data and be able to determine effect size, we investigated whether there was a difference in outcome before and after the standard dose of teicoplanin was increased due to a change in local protocol. Furthermore, we compared the characteristics of the missing data with our study population.

Standard care

Both piperacillin/tazobactam and teicoplanin were dosed according to national guidelines drafted by the Dutch Working Party on Antibiotic Policy (SWAB). Piperacillin/tazobactam was dosed at 4500 mg q8h for patients with normal renal function and q12h for patients with an eGFR of < 30 mL/min. Patients on teicoplanin always received a loading regimen followed by a maintenance dose, abiding by local protocol. Until 2018, our local protocol consisted of a single loading dose of 800 mg followed by a maintenance dose of 400 mg q24h. From 2018 onwards, our local protocol has changed to a loading regimen consisting of five consecutive doses of 12 mg/kg with a maximum of 800 mg per dose q12h, followed by a maintenance dose of 12 mg/kg with a maximum of 800 mg q24h. In patients with an eGFR < 50 mL/min, the maintenance dose was halved.

Data and outcome variables

The data collected for each patient included demographic data, hospital length of stay, admission type (ICU or non-ICU), serum creatinine levels until 7 days pre-admission, at admission and at start of antibiotics, and consecutive creatinine levels every 24 h after start of antibiotic treatment. Furthermore, the number of nephrotoxic agents (see Supplementary Information, available as Supplementary data at JAC Online) and the number of days on vasopressors were noted. Baseline serum creatinine was defined as serum creatinine levels either at start of antibiotics, at admission or up to 7 days pre-admission, depending on the available data. If multiple values were available, the one closest to the start of antibiotics was chosen. If multiple values per day were available, the earliest value was used.

Primary outcome

The incidence of AKI at 48–72 h after start of piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam + teicoplanin served as the primary outcome variable.

Secondary outcome

Secondary outcomes included change in serum creatinine at 48–72 h after start of piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam + teicoplanin expressed as a percentage relative to baseline, absolute values of serum creatinine at baseline and 48–72 h after start of antibiotic treatment, changes in serum creatinine relative to baseline for the ICU and non-ICU population, and the impact of covariates (age, sex, hospital length of stay, ICU admission status during antibiotic treatment, the number of different nephrotoxic drugs received during admission and amount of days on vasopressors during admission) on change in serum creatinine. We also investigated whether there was a difference in outcome before and after the standard dose of teicoplanin was increased due to a change in local protocol. Furthermore, we compared the characteristics of the missing data with our study population.
treatment, the number of different nephrotoxic drugs received during admission and number of days on vasopressors during admission served as covariates.\textsuperscript{31}

The data were analysed using Python 3.7.3 with the Pandas package (version 0.25.1), Numpy (version 1.17.0), Matplotlib (version 3.1.1) and Seaborn (version 0.9.0). Statistical analyses were performed using the Statsmodels (version 0.10.1) and Pingouin (version 0.3.2) packages. Significance was defined as a $P$ value $<0.05$.

**Results**

Of 8747 eligible patients, 4202 were included in the analysis (Figure 1). Of these, 3188 (75.9%) received piperacillin/tazobactam alone, 791 (18.8%) received teicoplanin alone and 223 (5.3%) received piperacillin/tazobactam + teicoplanin. Patient characteristics are described in Table 1. There are significant differences between groups with regard to age, sex, hospital length of stay, ICU admission, baseline eGFR and number of nephrotoxic drugs to the detriment of piperacillin/tazobactam + teicoplanin. Patients in the piperacillin/tazobactam + teicoplanin group, for instance, had a longer hospital length of stay (mean of 29.6 days [SD 26.2] versus 17.3 days [SD 17.8] for piperacillin/tazobactam and 22.5 days [SD 17.5] for teicoplanin, $P < 0.001$) and a higher ICU admission status (31.8% versus 15.4% for piperacillin/tazobactam and 12.8% for teicoplanin, $P < 0.001$). The medical subspecialty for which the patient was admitted for the non-ICU population is shown in Table 2.

**Primary outcome**

The incidence of AKI at 48–72 h after commencement of antibiotic therapy was 5.4% for piperacillin/tazobactam, 3.4% for teicoplanin and 11.7% for piperacillin/tazobactam + teicoplanin ($P < 0.001$) (Table 3). Logistic regression indicated statistical significance for piperacillin/tazobactam + teicoplanin ($P < 0.001$); significant founders were increased age ($P = 0.010$), male sex ($P = 0.025$) and ICU admission status ($P < 0.001$).

**Secondary outcome**

The change in serum creatinine from baseline to 48–72 h after commencement of antibiotic therapy was $-1.98\%$ (95% CI $-2.73$ to $-1.22$) for piperacillin/tazobactam, $-8.01\%$ (95% CI $-9.54$ to $-6.45$) for teicoplanin and $+1.61\%$ (95% CI $-2.25$ to $5.70$) for piperacillin/tazobactam + teicoplanin, indicating an improvement in renal function for monotherapy and a decline with combination therapy ($F = 27.07$, $P < 0.001$) (Figure 2). Post hoc comparisons using the Tukey HSD test showed a mean difference between piperacillin/tazobactam + teicoplanin and teicoplanin of 9.6% ($P = 0.001$) and a mean difference between piperacillin/tazobactam + teicoplanin and piperacillin/tazobactam of 3.6% ($P = 0.1057$), to the detriment of piperacillin/tazobactam + teicoplanin when compared with monotherapy. The mean difference between piperacillin/tazobactam and teicoplanin was 6.0% ($P = 0.001$).

Table 4 shows the median and IQRs for serum creatinine levels at baseline and at 48–72 h. Figure 2 shows the change in serum creatinine at 48–72 h after commencement of antibiotic treatment compared with baseline for the entire study population, the ICU population and the non-ICU population, with 95% CI. These results are also shown in Table 5.

To correct for differences in patient characteristics, age, sex, hospital length of stay, ICU admission and number of nephrotoxic drugs served as covariates in our multivariate linear regression. Our multivariate linear regression analysis showed a significant correlation between the antibiotic treatment (piperacillin/tazobactam, teicoplanin, piperacillin/tazobactam + teicoplanin) and change in serum creatinine at 48–72 h, with a $P$ value of 0.0016. Statistically significant founders were increased age ($P < 0.001$) and ICU admission status ($P < 0.001$). After correction for these founders, the adjusted mean differences were 10.8% between piperacillin/tazobactam + teicoplanin and piperacillin/tazobactam ($P = 0.010$) and 7.7% between piperacillin/tazobactam + teicoplanin and piperacillin/tazobactam ($P = 0.047$), to the detriment of piperacillin/tazobactam + teicoplanin when

![Figure 1. Flow diagram for patient inclusion and exclusion. RRT, renal replacement therapy; TZP+TEC, piperacillin/tazobactam + teicoplanin.](image-url)
compared with monotherapy, and 3.1% between piperacillin/tazobactam and teicoplanin ($P = 0.862$).

Table 6 shows the change in serum creatinine at 48–72 h after commencement of antibiotic treatment compared with baseline for the entire study population and for patients who received teicoplanin either before 2018 or from 2018 onwards, when the adjustment was made in our local protocol to increase the standard teicoplanin dose. These results are similar.

Table 7 shows the patient characteristics of the missing data compared with our study population. Notable differences are that the missing data include patients with a shorter hospital length of stay (11.2 versus 19.0 days) and fewer ICU patients (3.3% versus 15.8%).

**Discussion**

Our study suggests that the combination of piperacillin/tazobactam with teicoplanin is associated with a higher prevalence of AKI at 48–72 h after commencement of antibiotic treatment compared with monotherapy. Interestingly, when comparing serum creatinine at 48–72 h with baseline, renal function appears to improve with either piperacillin/tazobactam or teicoplanin, indicating an improvement in clinical status of the patient, but shows a slight decline in renal function for piperacillin/tazobactam! teicoplanin. The difference in change in renal function was statistically significant when piperacillin/tazobactam! teicoplanin was compared with teicoplanin, but not when compared with piperacillin/tazobactam monotherapy. In our post hoc analysis, however, after correction for confounders there was a statistically significant decline in renal function for piperacillin/tazobactam! teicoplanin when compared with both piperacillin/tazobactam treatment and teicoplanin treatment.

This decline in renal function with piperacillin/tazobactam! teicoplanin when compared with monotherapy could imply that these patients did not improve in clinical status as they may have been a sicker population to begin with, contrary to the patients on either piperacillin/tazobactam or teicoplanin. This is illustrated by the fact that the ICU admission status was higher in the piperacillin/tazobactam! teicoplanin group than in either the piperacillin/tazobactam or teicoplanin groups. In our multivariate analysis we corrected for severity of illness by taking ICU admission status into account. Our results may therefore suggest that the decline in renal function with piperacillin/tazobactam! teicoplanin is due to a synergistic antibiotic effect. Though it would have been preferable to use a more specific marker for severity of illness than ICU admission status, these data unfortunately were not available.

Several mechanisms have been proposed for possible synergy between piperacillin/tazobactam and vancomycin. One such hypothesis is that the addition of the β-lactamase inhibitor

| Table 1. Patient characteristics |
|---|
| | TZP | TEC | TZP + TEC | P value | Total |
| n | 3188 | 791 | 223 | <0.001 | 4202 |
| Age, years, mean (SD) | 63.4 (14.8) | 56.5 (16.5) | 60.7 (14.6) | <0.001 | 62.0 (15.4) |
| Sex, n (%) | | | | | |
| male | 1957 (61.4) | 455 (57.5) | 156 (70.0) | 0.003 | 2568 (61.1) |
| female | 1231 (38.6) | 336 (42.5) | 67 (30.0) | | 1634 (38.9) |
| Hospital length of stay, days, mean (SD) | 17.3 (17.8) | 22.5 (17.5) | 29.6 (26.2) | <0.001 | 19.0 (18.5) |
| ICU admission, n (%) | | | | | |
| no | 2697 (84.6) | 690 (87.2) | 152 (68.2) | <0.001 | 3539 (84.2) |
| yes | 491 (15.4) | 101 (12.8) | 71 (31.8) | | 1634 (38.9) |
| Baseline eGFR (mL/min), mean (SD) | 89.3 (37.2) | 92.2 (39.6) | 83.2 (35.1) | 0.006 | 89.6 (37.6) |
| Number of nephrotoxic drugs, mean (SD) | 1.6 (1.6) | 1.9 (1.7) | 2.3 (1.8) | <0.001 | 1.7 (1.6) |
| Days on vasopressors, mean (SD) | 3.9 (30.2) | 3.1 (7.9) | 3.4 (4.3) | 0.890 | 3.7 (26.8) |

TZP, piperacillin/tazobactam; TEC, teicoplanin; TZP + TEC, piperacillin/tazobactam + teicoplanin.

| Table 2. Medical subspecialty for the non-ICU population |
|---|
| Medical subspecialty | n (%) |
| Internal medicine | 1132 (32.0) |
| General surgery | 757 (21.4) |
| Pulmonology | 283 (8.0) |
| Cardiology | 226 (6.4) |
| Medium care | 209 (5.9) |
| Urology/gynaecology | 170 (4.8) |
| Trauma/orthopaedics | 163 (4.6) |
| Neurology/neurosurgery | 152 (4.3) |
| Psychiatry | 7 (0.2) |
| Other | 442 (12.5) |

| Table 3. Incidence of AKI at 48–72 h after commencement of antibiotic treatment for piperacillin/tazobactam (TZP), teicoplanin (TEC) and piperacillin/tazobactam! teicoplanin (TZP + TEC) |
|---|
| AKI, n (%) | 173 (5.4) | 27 (3.4) | 26 (11.7) |
| No AKI, n (%) | 3015 (94.6) | 764 (96.6) | 197 (88.3) |

JAC
Tazobactam may induce nephrotoxicity, as a decline in renal function is not seen with the combined use of vancomycin with other β-lactam antibiotics such as cefepime and meropenem. There are no studies comparing piperacillin and piperacillin/tazobactam with regard to nephrotoxicity. A matched-cohort study performed by Rutter and Burgess, in which patients were stratified according to vancomycin exposure, compared piperacillin/tazobactam with ampicillin/sulbactam with regard to renal
function. Results showed that the likelihood of AKI increased with the addition of vancomycin to piperacillin/tazobactam compared with piperacillin/tazobactam alone, but not when vancomycin was added to ampicillin/sulbactam. The authors conclude that the addition of a β-lactamase inhibitor is not responsible for the increased rates of AKI observed in patients treated with piperacillin/tazobactam + vancomycin. Another hypothesis suggests that the concomitant occurrence of interstitial nephritis (caused by piperacillin/tazobactam) and oxidative stress (caused by vancomycin) may lead to a stronger decline in renal function compared with monotherapy. However, a recent experimental study using a rat model showed no additional histopathological kidney injury with monotherapy. They did observe an increase in serum creatinine for both vancomycin and piperacillin/tazobactam, which they explain by proposing that there might be an interaction at the level of tubular secretion of creatinine. These proposed mechanisms have not been investigated for piperacillin/tazobactam + teicoplanin. Additionally, though vancomycin nephrotoxicity is dose dependent,1 when comparing patients with lower-dose teicoplanin from before 2018 with higher-dose teicoplanin from 2018 onwards, our results do not suggest a relationship between teicoplanin dose and decline in renal function. Due to their wide CIs these results should be interpreted with caution.

The occurrence of AKI with piperacillin/tazobactam + teicoplanin appears to be lower (11.7%) than reported in studies investigating piperacillin/tazobactam + vancomycin (11%–48.8% with an average of 27.4%). However, as studies investigating piperacillin/tazobactam + vancomycin used different definitions for AKI and methodologies different from those used in this study, this comparison should be made with great caution and no definitive conclusions should be drawn. Contrary to the studies that investigated the nephrotoxicity of concomitant piperacillin/tazobactam + vancomycin, we used a linear regression model, using the change in serum creatinine as a continuous variable, in addition to a logistic regression model, in which AKI was dichotomously defined, in order to preserve information such as the ability to calculate the degree of effect.33 The degree to which renal function declined with piperacillin/tazobactam + teicoplanin compared with monotherapy after correction for confounders was small: 10.8% when compared with teicoplanin and 7.7% when compared with piperacillin/tazobactam monotherapy. So even though our results appear to match the results of studies that investigated concomitant piperacillin/tazobactam + vancomycin with regard to renal function, our results indicate that the overall size of effect is much lower. The clinical relevance of these findings can therefore be questioned, as this effect seems to be small. The findings in this study should be weighed against the clinical indication for the combination of an antipseudomonal β-lactam antibiotic combined with a glycopeptide.

Our missing data consisted of patients with a shorter hospital length of stay and fewer ICU admissions, indicating that this group of patients was probably less severely ill than the patients in our study population. This can be expected as serum creatinine is less often determined in a healthier population compared with a sicker (or ICU) population. If these data had not been missing, however, the minor effect found in our study would probably have been even smaller.

Our study has several limitations that could interfere with these results. As the data were collected retrospectively from our electronic medical records, they are subject to potential biases and limited in completeness. Furthermore, there was no information available for several risk factors for kidney injury, such as the presence and duration of hypotension and volume depletion. Information on infection type, infecting organisms and susceptibility was also not available. When interpreting our results it should therefore be taken into account that residual confounding may play a role. This is especially so as the patient characteristics showed significant differences in various parameters. Additionally, as it is thought that nephrotoxicity of a glycopeptide might be dose dependent, nephrotoxicity could occur later than at the 48–72 h mark used in this study. Future studies should therefore consider taking the cumulative dose of teicoplanin and piperacillin/tazobactam into account with regard to renal function.

To our knowledge, this is the first study to investigate the nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin. The findings of our study suggest that even though piperacillin/tazobactam + teicoplanin is associated with an increase in AKI when compared with monotherapy, overall there is only a slight decline in renal function. Consequently, the clinical relevance is likely limited and these findings should be weighed against the clinical indication for the combination of an antipseudomonal β-lactam antibiotic combined with a glycopeptide. For clinical practice, our study suggests that with regard to renal function the combination of piperacillin/tazobactam and teicoplanin can probably be safely prescribed. Considering the limitations of our study, however, a propensity-matched study or a prospective study with a larger sample size are warranted to confirm these results.

### Table 7. Patient characteristics of missing data compared with the study population

| Study population | Missing data |
|------------------|--------------|
| n                | 4202         |
| Age, years, mean (SD) | 62.0 (15.4) |
| 4213 |
| Sex, n (%)        |              |
| male              | 2568 (61.1) |
| female            | 1634 (38.9) |
| Hospital length of stay, days, mean (SD) | 19.0 (18.5) |
| ICU admission, n (%) | 3539 (84.2) |
| Antibiotic treatment | 663 (15.8)  |
| Tazobactam        | 3188 (75.9) |
| TEC               | 791 (18.8)  |
| Tazobactam + TEC  | 223 (5.3)   |
| Baseline eGFR (mL/min), mean (SD) | 89.6 (37.6) |
| Number of nephrotoxic drugs, mean (SD) | 1.7 (1.6) |
| Days on vasopressors, mean (SD) | 3.8 (26.8) |

TZP, piperacillin/tazobactam; TEC, teicoplanin; TZP + TEC, piperacillin/tazobactam + teicoplanin.
Conclusions
To our knowledge, this is the first study to examine whether or not concomitant use of piperacillin/tazobactam and teicoplanin is associated with a decline in renal function when compared with monotherapy. Our study suggests that piperacillin/tazobactam + teicoplanin is associated with an increase in AKI compared with monotherapy. However, as the overall decline in renal function with piperacillin/tazobactam + teicoplanin is very small, its clinical relevance is likely limited. Our data therefore suggest that piperacillin/tazobactam and teicoplanin can probably be safely combined, though propensity-matched or prospective studies are warranted to further investigate these results.

Acknowledgements
We would like to thank Ton de Haan, statistician of the Radboud University, for his assistance regarding the statistical analyses.

Funding
This study was carried out as part of our routine work.

Transparency declarations
S.N. de W. reports grants from the European Union (H2020, IMI2), grants from Bill and Melinda Gates Foundation and grants from Health Holland, outside the submitted work. The foundations have no role in the design, implementation, interpretation or reporting of the study. The other authors have no conflicts of interest relevant to this article to declare.

Supplementary data
Supplementary Information is available as Supplementary data at JAC Online.

References
1 Elyasi S, Khalili H, Dasthti-Khavidaki S et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. a literature review. Eur J Clin Pharmacol 2012; 68: 1243–55.
2 Arnaud FCDS, Libório AB. Attributable nephrotoxicity of vancomycin in critically ill patients: a marginal structural model study. J Antimicrob Chemother 2020; 75: 1031–7.
3 Filipone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacal Ther 2017; 102: 459–69.
4 Kang H-K, Park Y. Glycopeptide antibiotics: structure and mechanisms of action. J Bacterial Virol 2015; 45: 67–78.
5 Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069–79.
6 Peng Y, Ye X, Li Y et al. Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials. PLoS One 2013; 8: e79782.
7 Bugano DD, Cavalcanti AB, Goncalves AR et al. Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection. Einstein (Sao Paulo) 2011; 9: 265–82.
8 Cavalcanti AB, Goncalves AR, Almeida CS et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2008; issue 6: 1–63.
9 Hammond DA, Smith MN, Li C et al. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 2017; 64: 666–74.
10 Luther MK, Timbrook TT, Caffrey AR et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med 2018; 46: 12–20.
11 Bellos I, Kareageorgiou V, Pergialiots V et al. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect 2020; 6: 696–705.
12 Gomes DM, Smotherman C, Birch A et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or ceftazidime. Pharmacotherapy 2013; 34: 662–9.
13 Navalekele B, Pogue JM, Karino S et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis 2017; 64: 116–23.
14 Mullins BP, Kramer CJ, Bartel BJ et al. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: a prospective, multicenter study. Ann Pharmacother 2018; 52: 639–44.
15 Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime and morgenem and vancomycin. J Pharm Pract 2017; 30: 209–13.
16 Robertson AD, Li C, Hammond DA et al. Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem. Pharmacotherapy 2018; 38: 1184–93.
17 Triffeault-Fililt C, Mabrut E, Corbin K et al. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study. J Antimicrob Chemother 2020; 75: 2299–306.
18 Kalligeros M, Karageorgos SA, Shehadeh F et al. The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: a systematic review and meta-analysis. Antimicrob Agents Chemother 2019; 63: e01572–19.
19 Downes KJ, Cowden C, Laskin BL et al. Association of acute kidney injury with concomitant vancomycin and piperacillin-tazobactam treatment among hospitalized children. JAMA Pediatr 2017; 171: e173219.
20 Cook KM, Gillon J, Grasso AG et al. Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study. J Pediatr Infect Dis Soc 2019; 8: 221–7.
21 Bleivins AM, Lashinsky JN, McCammon C et al. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother 2019; 63: 1–10.
22 Inage S, Nakamura S, Isode Y et al. Acute kidney injury in non-intensive care unit and intensive care unit patients treated with vancomycin and piperacillin-tazobactam. J Jpn Med Soc 2019; 87: 66–72.
23 Kang S, Park J, Yu YM et al. Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with β-lactams in the intensive care unit. PLoS One 2019; 14: e0217908.
24 Molina KC, Barletta JF, Hall ST et al. The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime. J Intensive Care Med 2019; doi:10.1177/088506619828290.
25 Schreier DJ, Kashani KB, Sukhuja A et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin. Clin Infect Dis 2019; 68: 1456–62.
26 Buckley MS, Hartsock NC, Berry AJ et al. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit. J Crit Care 2018; 48:32–8.
27 Pais GM, Liu J, Avedissian SN et al. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother 2020; 75:1228–36.
28 Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–12.
29 Kellum JA, Lameire N, Aspelin P et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2:1–138.
30 Cazaubon Y, Venisse N, Mimoz O et al. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen. J Antimicrob Chemother 2017; 72:2804–12.
31 Rutter WC, Burgess DR, Talbert JC et al. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis. J Hosp Med 2017; 12:77–82.
32 Rutter WC, Burgess DS. Acute kidney injury in patients treated with IV β-lactam/β-lactamase inhibitor combinations. Pharmacotherapy 2017; 37:593–8.
33 Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009; 8:50–61.